| Description | ABT530 (Pibrentasvir) is an HCV NS5A inhibitor with EC50s ranging from 1.4-5.0 pM against HCV replicons containing NS5A from genotypes 1-6. |
| Target activity | HCV NS5A:1.4-5.0 pM(EC50) |
| Synonyms | ABT 530, ABT-530, 哌仑他韦, Pibrentasvir |
| molecular weight | 1113.18 |
| Molecular formula | C57H65F5N10O8 |
| CAS | 1353900-92-1 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 50 mg/mL (44.92 mM), Sonication is recommended. |
| References | 1. Ng TI, et al. In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir. Antimicrob Agents Chemother. 2017 Apr 24;61(5). pii: e02558-16. 2. Pham LV, et al. HCV Genotype 6a Escape From and Resistance to Velpatasvir, Pibrentasvir, and Sofosbuvir in Robust Infectious Cell Culture Models. Gastroenterology. 2018 Jun;154(8):2194-2208.e12. |